NK92MI细胞

NK92MI/NK92MI细胞系/NK92MI细胞株/NK92MI恶性非霍奇金淋巴瘤患者的自然杀伤细胞

Cell line name NK-92MI

Synonyms NK-92 MI; NK-92 mi; NK92-MI; NK92MI; NK-92 transfected with MFG-hIL2

Accession CVCL_3755

Resource Identification Initiative To cite this cell line use: NK-92MI (RRID:CVCL_3755)

Comments Group: Patented cell line.

Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6671.

Population: Caucasian.

Characteristics: No longer dependent on IL2.

Microsatellite instability: Stable (MSS) (Sanger).

Genetic integration: Method=Transfection/transduction; Gene=HGNC; 6001; IL2.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers of NK-92MI. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support.

Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.

Cell type: Natural killer cell; CL=CL_0000623.

PubMed=10365666; DOI=10.1089/10430349950018030

Tam Y.K., Maki G., Miyagawa B., Hennemann B., Tonn T., Klingemann H.-G.

Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy.

Hum. Gene Ther. 10:1359-1373(1999)

 

Patent=US8034332

Klingemann H.-G.

Interleukin-secreting natural killer cell lines and methods of use.

Patent number US8034332, 11-Oct-2011

 

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mir T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

 

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

 

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775

Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Pan-cancer proteomic map of 949 human cell lines.

Cancer Cell 40:835-849.e8(2022)